Blog April 2, 2020
USPTO Guidance on Natural Product Development
- Person title
This article appeared in Pharmaceutical Compliance Monitor, December 5, 2014 and is reproduced with permission.
To be eligible for patent protection, an invention must meet several requirements under U.S. patent law. One of those requirements — whether the patent claims eligible subject matter (35 U.S.C. § 101) — has been front and center in several recent Supreme Court cases. Two of those cases directly concern life science inventions—the Mayo and Myriad cases—while a third—Alice Corp.—is likely to have broad applicability to any patentable method.
In light of these cases, the United States Patent and Trademark Office (USPTO) recently issued guidelines to patent examiners on how to analyze claims reciting or involving "Laws of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products."
The analytical framework of the guidance involves a "decision tree" with three sequentially addressed questions:
- Is the claimed invention directed to a process, machine, manufacture, or composition of matter? (If no, the claim is ineligible.)
- If yes, does the claim "recite or involve" one or more judicial exception(s)? Exceptions include laws of nature/natural principles, natural phenomena, natural products, and abstract ideas, which are examined under a different guidance. (If no, the claim is eligible.)
- If yes, or if there is any doubt, does the claim as a whole recite something significantly different than the judicial exception(s)?
After meeting much hostility from the life sciences patent community—unlike similar guidance on high tech related inventions, which was generally well-received—the USPTO has stated that it will revise the Mayo/Myriad guidance, already committing to change Questions 2 and 3 to more closely track Supreme Court law. For example, Question 2 will ask whether the claim is "directed to" one or more judicial exceptions, after commentators pointed out that almost all life sciences inventions may be said to "involve" a natural product or phenomenon. Similarly, Question 3's "significantly different" standard—which was the USPTO's effort to apply simultaneously the Mayo and Chakrabarty decisions—will likely be changed to use a formulation directly from the Supreme Court's cases.
Please read "USPTO Guidance on Natural Product Development" for the rest of this article. If you have any questions about this article or would like to discuss this topic further, please contact the author, Jonathan Singer.
The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.
Q&A July 10, 2019
Q&A with Jon Singer for Corporate Counsel Business Journal
Article April 22, 2014
Understanding Legal Trends in the Life Sciences Industry
Article March 22, 2023
Principals Anita Meiklejohn and Caleb Bates Co-Author Article for One Nucleus Annual Review 2023
Blog March 17, 2023
Legal Alert: The USPTO’s Transition to Electronic Patent Issuance and Reduction in Period Between Issue Notification and Issue Date
Article March 8, 2023
Senior Principal Terry Mahn Authors Medical Device + Diagnostic Industry Article "This Company's False Compliance With CISPR 11 Resulted in a $12 Million FCA...
Blog March 2, 2023
Texas Patent Litigation Monthly Wrap-Up: February 2023
Article February 17, 2023
Principals Patrick Darno and Peter Fasse Author "Patent Strategies for Protecting Bioinformatics Inventions" for IAM
Blog February 10, 2023
Texas Patent Litigation Monthly Wrap-Up: January 2023
Blog February 7, 2023
ITC Monthly Wrap-Up: January 2023
Article February 3, 2023
Fish & Richardson Attorneys Author IAM Article "Neglect Begets Opportunity in Femtech IP"
Blog January 17, 2023
Minnesota Patent Litigation Wrap-Up: Q4 2022
Blog January 17, 2023
Biosimilars 2022 Year in Review